Journal Information
Vol. 98. Issue 7.
Pages 491-493 (September 2007)
Vol. 98. Issue 7.
Pages 491-493 (September 2007)
Case reports
Full text access
Capecitabine Induced Hyperpigmentation
Hiperpigmentación Secundaria a Capecitabina
Visits
9444
C. Vázquez-Bayo, A.L. Rodríguez-Bujaldón, R. Jiménez-Puya
Corresponding author
JIMPUYA@terra.es

Correspondence: Servicio de Dermatología. Hospital Universitario Reina Sofía. Avda. Menéndez Pidal, s/n. 14004 Córdoba. Spain.
, M. Galán-Gutiérrez, J.C. Moreno-Giménez
Servicio de Dermatología, Hospital Universitario Reina Sofía, Córdoba, Spain
This item has received
Article information
Abstract

Capecitabine is an antineoplastic agent used for the treatment of patients with metastatic solid tumors (breast and colon). Different adverse effects have been recognized, among which we find the muco-cutaneous ones and, specifically, hyperpigmentation. We report a case of localized cutaneous hyperpigmentation secondary to capecitabine in a woman that underwent surgery for breast cancer and was receiving this drug for a month. The start of therapy was associated with dysesthesia and hyperpigmentation of the hands and feet. The pathogenesis of such manifestations is unknown. Other reported cutaneous adverse effects associated with this drug involve the nails producing onycholysis, fragility, discoloration and dystrophy.

Key words:
capecitabine
hyperpigmentation
breast cancer
Resumen

La capecitabina es un agente antineoplásico utilizado para el tratamiento de pacientes con metástasis de tumores sólidos (mama y colon) en estadio avanzado. Se reconocen distintos efectos adversos, entre los cuales se encuentran los cutáneo-mucosos y, en concreto, la hiperpigmentación. Presentamos un caso de hiperpigmentación cutánea localizada secundaria a capecitabina en una mujer intervenida de cáncer de mama y en tratamiento durante un mes con este fármaco. El inicio del tratamiento se asoció con disestesias a nivel de manos y pies, así como aumento de la pigmentación de las mismas. La etiopatogénesis de tales manifestaciones es desconocida. Otros efectos adversos descritos, desde el punto de vista dermatológico, asociados a este fármaco asientan en uñas produciendo onicolisis, fragilidad, decoloración y distrofia.

Palabras clave:
capecitabina
hiperpigmentación
cáncer de mama
Full text is only aviable in PDF
References
[1.]
V.G. Kaklamani, W.J. Gradishar.
Role of capecitabine (Xeloda®) in breast cancer.
Expert Rev Anticancer Ther, 3 (2003), pp. 137-144
[2.]
A.D. Seidman.
Monotherapy options in the management of metastatic breast cancer.
Semin Oncol, 30 (2003), pp. 6-10
[3.]
P. Narasimhan, S. Narasimhan, I.F. Hitti, M. Rachita.
Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of the literature.
Cutis, 73 (2004), pp. 101-106
[4.]
K.L. Maino, C. Norwood, M.E. Stashower.
Onycholysis with the appearance of a “sunset” secondary to capecitabine.
Cutis, 72 (2003), pp. 234-236
[5.]
J.C. Pui, S. Meehan, T. Moskovits.
Capecitabine induced cutaneous hyperpigmentation: report of a case.
J Drugs Dermatol, 1 (2002), pp. 202-205
[6.]
B. Reigner, K. Blesch, E. Weidekamm.
Clinical pharmacokinetics of capecitabine.
Clin Pharmacokinet, 40 (2001), pp. 85-104
[7.]
M. Dooley.
Capecitabine.
Drug, 58 (1999), pp. 69-76
[8.]
K. Bell, A. Perna, S. Hsu.
Mucositis as a treatment-limiting side effect in the use of capecitabine for the treatment of metastatic breast cancer.
J Am Acad Dermatol, 45 (2001), pp. 790-791
[9.]
E. Llistosella, A. Codina, R. Álvarez, R.M. Pujol, J.M. de Moragas.
Tegafur-induced acral hyperpigmentation.
Cutis, 48 (1991), pp. 205-207
[10.]
B.J. Allen, D. Parker, A.L. Wright.
Reticulate pigmentation due to 5-fluorouracil.
Int J Dermatol, 34 (1995), pp. 219-220
[11.]
S.J. Vukelja, M.W. Bonner, M. McCollough, P.W. Cobb, D.A. Gaule, P.J. Fanucchi, et al.
Unusual serpentine hyperpigmentation associated with 5-fluorouracil. Case report and review of cutaneous manifestations associated with systemic 5-fluorouracil.
J Am Acad Dermatol, 25 (1991), pp. 905-908
[12.]
S. Fukushima, N. Hatta.
Atypical moles in a patient undergoing chemotherapy with oral 5-fluorouracil.
Br J Dermatol, 151 (2004), pp. 698-700
[13.]
G. Chen, Y. Chen, M. Hsu, C.J. Tsao, W.C. Chen.
Onychomadesis and onycholysis associated with capecitabine.
Br J Dermatol, 45 (2001), pp. 521-522
Copyright © 2007. Academia Española de Dermatología y Venereología and Elsevier España, S.L.
Download PDF
Idiomas
Actas Dermo-Sifiliográficas
Article options
Tools
es en

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?